Table 3. CLL patients with TP53 abnormalities.
| Patient Number | Del 17p (FISH) | P53 Functional Assessment | TP53 Mutational Status |
|---|---|---|---|
| 25 | 23% [46/200] | Dysfunctional | c.536A>G/p.H179R (exon 5) |
| 30 | 53% [107/200] | Dysfunctional | c.425C>G/p.P142R (exon 5) + c.665C>T/p.P222L (exon 6) |
| 53 | 89% [178/200] | Dysfunctional | Unmutated (exons 5–8) |
| 59 | 17% [34/200] | Dysfunctional | c.Del790–792CTA/p.Del264L (exon 8) |
| 62 | 97% [195/200] | Dysfunctional | c.417G>T/p.V173L (exon 5) |
| 67 | 90% [181/200] | Dysfunctional | c.524G>A/p.R175H (exon 5) |
| 71 | 96% [193/200] | Dysfunctional | c.184G>T, p.E62X (exon 4) |
| 72 | 93% [186/200] | Dysfunctional | p.R273H (exon 8) |
| 73 | 97% [195/200] | Dysfunctional | c.818G>A, p.R273H (exon 8) |
| 74 | 16% [33/200] | Dysfunctional | c.536C>T/p.H179Y (exon 5) |
| 79 | 0% [0/200] | Dysfunctional | IVS9+2A>G (intron 9) (homozygous) |
The assessment of the functional status of P53 in CLL cells was based on induction of P21 and P53 protein expression using etoposide and nutlin-3a [39]. The detection of TP53 mutations was performed as described in Methods. FISH: score of interphasic cells with an abnormality. Del, deletion.